Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold
by Tristan Rich · The Markets DailyCentury Therapeutics (NASDAQ:IPSC – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a research report on Tuesday, September 29th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Century Therapeutics has a consensus rating of “Hold” and an average target price of $4.75.
Read Our Latest Report on Century Therapeutics
Century Therapeutics Stock Performance
NASDAQ IPSC opened at $1.65 on Friday. The stock’s fifty day moving average is $1.64 and its two-hundred day moving average is $2.06. The firm has a market capitalization of $299.64 million, a P/E ratio of -2.58 and a beta of 1.78. Century Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $3.04.
Century Therapeutics (NASDAQ:IPSC – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, sell-side analysts forecast that Century Therapeutics will post -0.51 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of IPSC. Seven Fleet Capital Management LP purchased a new position in shares of Century Therapeutics during the 1st quarter worth approximately $9,826,000. Commodore Capital LP acquired a new stake in Century Therapeutics in the 1st quarter valued at approximately $19,652,000. BlackRock Inc. acquired a new stake in Century Therapeutics in the 2nd quarter valued at approximately $19,825,000. Rock Springs Capital Management LP acquired a new stake in Century Therapeutics in the 1st quarter valued at approximately $2,948,000. Finally, Trails Edge Capital Partners LP purchased a new stake in Century Therapeutics in the second quarter valued at approximately $10,130,674. Hedge funds and other institutional investors own 50.20% of the company’s stock.
Century Therapeutics Company Profile
Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.
Further Reading
- Five stocks we like better than Century Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced